Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Stockwatch: Bluebird, Arrowhead And Short Memories

Dec 05 2016

• By Andy Smith

Stockwatch_1200x675 — Andy Smith gives an investor's perspective on life science companies

Related Content

Roche's Transfer Of Assets To Arrowhead May Create Most-Comprehensive RNAi Firm

Oct 25 2011

Arrowhead Tumbles As FDA Puts A Clinical Hold On Novel HBV Therapy Trial

Nov 09 2016

Arrowhead Misfires: Abandons Clinical Programs, But Keeps Amgen Deal

Dec 01 2016

Pfizer pulls PAH drug Thelin from market after unpredictable deaths

Dec 13 2010

Stockwatch: Alnylam Helps Nucleic Acid Drugs Degrade

Oct 10 2016

Arrowhead gets $35m bargain for Novartis RNAi assets with Alnylam targets

Mar 06 2015

Stockwatch: A Christmas Medical Conference

Dec 14 2015

Stockwatch: UniQure's guile and the dubious promise of gene therapy

Apr 14 2015

Deal Watch: Zymeworks Adds Daiichi To List Of Partners In I-O Cross Collaboration

Sep 30 2016

Related Companies

Arrowhead Pharmaceuticals, Inc.

Roche Holding AG

Novartis AG

Amgen, Inc.

uniQure N.V.

Bristol Myers Squibb Company

Genetix Biotherapeutics

Bristol Myers Squibb Company

Additional Topics

Clinical Trials ImmunoOncology Strategy Commercial Cancer Infectious Diseases BioPharmaceutical

More from Clinical Trials

More from R&D

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window